aod9604 human clinical trials weight loss results AOD 9604 vs. Semaglutide: A Comparison AOD-9604: Weight Loss, Evidence, Safety

While limited evidence supports this, the practice is common

Rather than asking what is the dose, which presumes the compound is already the answer, the stronger questions open up the actual decision

Free fatty acids are released into the bloodstream, but unless you are in a caloric deficit or exercising to oxidize those fatty acids, they are simply re-esterified and stored again

If you want a safe but effective weight loss treatment option, you may want to talk to your doctor about AOD 9604 peptide therapy

The numbers are staggering

However, in the pivotal Phase IIb trial, it failed to demonstrate statistically significant weight loss compared to placebo at the primary endpoint, leading the developer (Metabolic Pharmaceuticals Ltd.) to terminate the commercial program